Open an account

Madrigal Pharmaceuticals

MDGL · NASDAQ

$467.54+$20.45 (+4.57%)TodayMarket closed ·
Prev close $447.09

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The firm is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Employees
915
Headquarters
West Conshohocken, Pennsylvania
Listed
Feb 6, 2007
Sector
Health Care
Industry
Biotechnology
Website
madrigalpharma.com

MDGL key statistics

Market cap
10.33B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
281.92K
Volume
407.96K
Open price
$449.80
High today
$470.30
Low today
$448.52
52 Week high
$615.00
52 Week low
$393.61

Madrigal Pharmaceuticals (MDGL) at a glance

As of Oct 20, 2026, Madrigal Pharmaceuticals (MDGL) shares are priced at $467.54, giving the company a market cap of 10.33B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $448.52 and $470.30. The current price is 4.2% above the day's low and 0.6% below its high.

Volume so far is 407.96K shares, above the average of 281.92K shares a day.

Over the past year Madrigal Pharmaceuticals has ranged from $393.61 to $615.00, and now sits 33% of the way up that range.

Madrigal Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.99 per share against an estimate of -$2.62.

The average analyst price target is $695.64, 48.8% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

93%of 15 analyst ratings say Buy
  • Buy93.3%
  • Hold6.7%
  • Sell0.0%
Price target · 21 analystsAvg $695.64
Low
$548.43
Now
$467.54
High
$1,010.10

MDGL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 29.1% on average.

  1. Q3 FY24: reported -$4.92 per share against an estimate of -$7.05
  2. Q4 FY24: reported -$2.71 per share against an estimate of -$4.33
  3. Q1 FY25: reported -$3.32 per share against an estimate of -$3.84
  4. Q2 FY25: reported -$1.90 per share against an estimate of -$3.71
  5. Q3 FY25: reported -$4.96 per share against an estimate of -$2.12
  6. Q4 FY25: reported -$2.57 per share against an estimate of -$0.6872
  7. Q1 FY26: reported -$3.25 per share against an estimate of -$4.11
  8. Q2 FY26: reported -$1.99 per share against an estimate of -$2.62

MDGL news

  • Erica Kollmann

    This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold

  • 4 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releasePRNewswire

    Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

  • Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call

  • Press releaseBusiness Wire

    Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

  • Press releasePRNewswire

    The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

  • Press releasePRNewswire

    Advanced Cell-based Therapy Booming the Success for Healthcare Sector

  • Press releasePRNewswire

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Similar companies

Companies in the same industry as Madrigal Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.